Validation Master Planning Capabilities
Kymanox caters to your specific needs to ensure your Validation Master Plan (VMP) is set up for success.
Meet our Validation Master Planning Solutions Experts
Faith Fraley
PRINCIPAL ENGINEER


Markets That Benefit from Our Validation Master Planning Solutions
Combination Products
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
Biologics & Cell and Gene Therapy Services
We understand why “the product is the process” and how to implement solutions to your unique challenges.




The Kymanox Difference
At Kymanox we are more than consultants. We are partners with our clients and create custom solutions that meet each client’s unique needs.

"Right First Time” Execution
Our branded methodology, Ideal Knowledge TransferTM, combines technical project management, fundamental engineering practices, quality and regulatory expertise, and business acumen.

Proven Broad Expertise
Our team of experts is focused on life sciences with extensive experience across drug and device development. No matter your challenge, we can help you conquer it.

Flexibility & Agility
At Kymanox, we make it easy for clients to get the solutions they need, when they need it. Clients tell us our flexibility is one of the key reasons they keep coming back.
Frequently Asked Validation Master Planning Questions (FAQs)
Why is there so much documentation involved with Validation?
Proper documentation is required to capture the planning, requirements, testing, and quality approvals associated with a system. Without documented evidence, there is no proof that a system was evaluated and qualified appropriately. Gaps in documentation can reflect gaps in control. On the bright side, the level of documentation should be appropriate for the system. If a system has low impact to the quality of the product or patient impact, the level of documentation should reflect that. For example, a formal risk assessment may not be necessary and risks can therefore be discussed elsewhere such as in the Validation Plan or associated protocol.
Read the Latest at Kymanox
Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider
Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider
Integrating the well-respected and trusted Agilis brand and team extends Kymanox’s capabilities in human factors (HF) by adding incredible talent, the ability to conduct HF stu...
Investment Reports Interview with Stephen M. Perry, CEO and Founder of Kymanox
Kymanox CEO and Founder, Stephen M. Perry was interviewed as part of the Investment Reports article, The New Era of Life Sciences 2023, published on 17MAR23,
What were the circumstances that brought Kymanox to life and what does your present foo...
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...